Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Original Article
Coagulation parameters and prognosis analysis in COVID-19 patients
Aims: There are many factors that affect morbidity and mortality in COVID-19. Coagulopathy is thought to be one of the important mechanisms in COVID-19 mortality. In this study, it was aimed to investigate coagulation factors and their relationship with prognosis in COVID-19.
Methods: Patients diagnosed with COVID-19 were retrospectively reviewed in our hospital. The patients' demographic data, laboratory data on admission to the hospital, intensive care admissions, and surveillance were recorded. Patients were divided into two groups; Group 1 is non-critical patients followed up in the clinic, Group 2 is critical patients who need treatment in the intensive care unit.
Results: 403 patients followed up for COVID-19 were analyzed. It was determined that the average age of the patients in Group 1 was statistically significantly lower than those in Group 2. (1: 45.28 ± 15.31 vs. 2: 60.15 ± 15.72, respectively, p <0.001). It was observed that the rates of HT, DM, CHD, and COPD in Group 2 were statistically significantly higher than Group 1 (p <0.05). While APTT values were similar in both groups, D-Dimer values were significantly higher in Group 2. As QSOFA, SIC, DIC, and coagulation marker scores increased, the percentage of patients with death increased significantly (p <0.05). Age, HT, COPD, PT, and high fibrinogen levels were found to increase the mortality risk rates statistically (p <0.05).
Conclusion: It was determined that the most important factors determining mortality in COVID-19 are COPD and HT. APTT and D-dimer values were not found to be a prognostic factor in terms of mortality. However, PT, fibrinogen, and age are poor prognostic factors and can be used to predict mortality requiring intensive care.

1. Long B, Carius BM, Chavez S, et al. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am J Emerg Med. 2022;54:46-57.
2. Voicu S, Delrue M, Chousterman BG, et al. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications. Eur Rev Med Pharmacol Sci. 2020;24:9161-9168.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
5. Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761.
6. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
8. Girgin S, Aksun M, T&uuml;zen AS, et al. Effects of comorbidities associated with COVID-19 cases in intensive care unit on mortality and disease progression. Eur Rev Med Pharmacol Sci. 2023;27(8):3753-3765.
9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
10. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
11. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145-148.
12. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombol. 2021;1107-1110.
13. Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in caucasian patients. Br J Haematol. 2020;189(6):1044-1049.
14. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.
15. Yu M, Nardella A, Pechet L. Screening tests of disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis. Crit Care Med. 2000;28(6):1777-1780.
16. Taylor F, Toh C-H, Hoots K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(11):1327-1330.
17. Chandrashekar V. DIC score: statistical relationship with PT, APTT, and Simplified scoring systems with combinations of PT and APTT. ISRN Hematol. 2012;1-4.
18. Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic strategies. Clin Appl Thromb. 2018;24(9):8-28.
19. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11(4):761-767.
20. Hu Y, Wang YD. How I treat disseminated intravascular coagulation. Zhonghua Xue Ye Xue Za Zhi. 2017;38(5):371-374.
21. Vidali S, Morosetti D, Granai AV, Legramante JM, Buonomo OC, Argir&ograve; R. Splenoportal-mesenteric axis thrombosis and splenic artery occlusion as initial presentations of COVID-19 disease. Eur Rev Med Pharmacol Sci. 2021;25(3):1680-1683.
22. Dwiputra Hernugrahanto K, Novembri Utomo D, Hariman H, et al. Thromboembolic involvement and its possible pathogenesis in COVID-19 mortality: lesson from post-mortem reports. Eur Rev Med Pharmacol Sci. 2021;25(3):1670-1679.
23. Taşkın &Ouml;, Soylu VG, Demir U, et al. Retrospective evaluation of critical geriatric and adult COVID-19 patients. Kastamonu Med J. 2021;1(3): 71-74.
24. Dereli N, Babayiğit M, Ko&ccedil; F, et al. Type-H, and Type-L COVID-19: are they different subtypes or the same? Eur Rev Med Pharmacol Sci. 2022;26(9):3367-3373.
25. Demir U, Soylu VG, Taşkın &Ouml;, Yılmaz A. Change of critical COVID-19 disease in time. Kastamonu Med J. 2022;2(2): 35-38.
26. Dereli N, Babayigit M, Ko&ccedil; F, et al.The relationship between inflammatory parameters and mortality in COVID-19 patients treated in the intensive care unit.Eastern J Med. 2022;27(1):146-154
27. Venkata C, Kashyap R, Christopher Farmer J, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1(1):1-10.
28. McGonagle D, O&rsquo;Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):437-445.
Volume 3, Issue 4, 2023
Page : 198-203